124 related articles for article (PubMed ID: 19271134)
1. Histamine dihydrochloride and interleukin-2 in acute myeloid leukemia--background and results.
Brune M; Romero AI; Hellstrand K
Inflamm Res; 2009 Apr; 58 Suppl 1():4-8. PubMed ID: 19271134
[No Abstract] [Full Text] [Related]
2. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML.
Romero AI; Thorén FB; Aurelius J; Askarieh G; Brune M; Hellstrand K
Scand J Immunol; 2009 Sep; 70(3):194-205. PubMed ID: 19703009
[TBL] [Abstract][Full Text] [Related]
3. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
Thorén FB; Romero AI; Brune M; Hellstrand K
Expert Opin Biol Ther; 2009 Sep; 9(9):1217-23. PubMed ID: 19653866
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.
Martner A; Thorén FB; Aurelius J; Söderholm J; Brune M; Hellstrand K
Expert Rev Hematol; 2010 Aug; 3(4):381-91. PubMed ID: 21083028
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on histamine dihydrochloride in acute myeloid leukaemia.
Yang LP; Perry CM
Drugs Aging; 2011 Apr; 28(4):325-9. PubMed ID: 21428467
[TBL] [Abstract][Full Text] [Related]
6. Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.
Buyse M; Michiels S; Squifflet P; Lucchesi KJ; Hellstrand K; Brune ML; Castaigne S; Rowe JM
Haematologica; 2011 Aug; 96(8):1106-12. PubMed ID: 21546500
[TBL] [Abstract][Full Text] [Related]
7. Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma.
Perz JB; Ho AD
Future Oncol; 2008 Apr; 4(2):169-77. PubMed ID: 18407731
[TBL] [Abstract][Full Text] [Related]
8. Postconsolidation immunotherapy in leukaemia remission.
Nelson R
Lancet Oncol; 2006 May; 7(5):367. PubMed ID: 16696159
[No Abstract] [Full Text] [Related]
9. Histamine dihydrochloride and interleukin-2 in the treatment of acute myeloid leukemia.
Stadtmauer EA
Semin Oncol; 2002 Jun; 29(3 Suppl 7):47-51. PubMed ID: 12068389
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia.
Rydström A; Hallner A; Aurelius J; Sander FE; Bernson E; Kiffin R; Thoren FB; Hellstrand K; Martner A
J Leukoc Biol; 2017 Aug; 102(2):467-474. PubMed ID: 28235771
[TBL] [Abstract][Full Text] [Related]
11. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.
Brune M; Castaigne S; Catalano J; Gehlsen K; Ho AD; Hofmann WK; Hogge DE; Nilsson B; Or R; Romero AI; Rowe JM; Simonsson B; Spearing R; Stadtmauer EA; Szer J; Wallhult E; Hellstrand K
Blood; 2006 Jul; 108(1):88-96. PubMed ID: 16556892
[TBL] [Abstract][Full Text] [Related]
12. Histamine dihydrochloride: in the management of acute myeloid leukaemia.
Yang LP; Perry CM
Drugs; 2011 Jan; 71(1):109-22. PubMed ID: 21175244
[TBL] [Abstract][Full Text] [Related]
13. Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells.
Aurelius J; Martner A; Brune M; Palmqvist L; Hansson M; Hellstrand K; Thoren FB
Haematologica; 2012 Dec; 97(12):1904-8. PubMed ID: 22689678
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
Rizzieri DA; O'Brien JA; Broadwater G; Decastro CM; Dev P; Diehl L; Beaven A; Lagoo A; Gockerman JP; Chao NJ; Moore JO
Cancer; 2009 Jul; 115(13):2922-9. PubMed ID: 19452542
[TBL] [Abstract][Full Text] [Related]
15. Response in acute myeloid leukemia.
Estey E
Clin Adv Hematol Oncol; 2008 Feb; 6(2):113-7. PubMed ID: 18347562
[TBL] [Abstract][Full Text] [Related]
16. On the road to new drugs in acute myeloid leukemia.
Löwenberg B
J Clin Oncol; 2007 Jan; 25(1):1-2. PubMed ID: 17146103
[No Abstract] [Full Text] [Related]
17. Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype.
Nilsson MS; Hallner A; Brune M; Nilsson S; Thorén FB; Martner A; Hellstrand K
Hum Vaccin Immunother; 2020; 16(1):109-111. PubMed ID: 31242079
[TBL] [Abstract][Full Text] [Related]
18. Treatment of acute myelogenous leukemia.
Ghaddar H; Anderlini P; Estey E
N Engl J Med; 1995 Jun; 332(25):1717-8; author reply 1718-9. PubMed ID: 7760880
[No Abstract] [Full Text] [Related]
19. The long road to a cure for acute myelocytic leukemia: from intensity to specificity.
Vaughan WP; Karp JE
J Clin Oncol; 2008 Jul; 26(21):3475-7. PubMed ID: 18640926
[No Abstract] [Full Text] [Related]
20. Histamine as an adjunct to immunotherapy.
Naredi P
Semin Oncol; 2002 Jun; 29(3 Suppl 7):31-4. PubMed ID: 12068386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
